Kornimate/medical-research-clean huggingface dataset:
preoperative micronized flavonoid fraction (mff) use in multimodal anesthesia in anorectal surgery

Conditions: Hemorrhoids; Hemorrhoid Pain; Hemorrhoidal Bleeding

Summary: aim: to assess the efficiency of the micro-flavonoid fraction (mmf) administration prior to anorectal surgery with spinal anesthesia on postoperative pain severity reduction. methods: patients who meet the following criteria are included: participants must be diagnosed with surgical treatment of anorectal diseases. all participants are randomly divided into 2 groups: the first one gets a tablet with 1000 mg mff (detralex®), the second one gets a tablet containing starch per os 14 days before surgery (72 participants per arm). then patients of each group will continue mff administration for 30 days after surgery. patients of both arms receive spinal anesthesia and undergo surgery. following the procedure the primary and secondary outcomes are evaluated: frequency of the opioid drugs intake, the severity of the postoperative pain syndrome, duration and frequency of other drugs intake, readmission rate, overall quality of life, time from the procedure to returning to work and the complications rate, c-reactive protein level. discussion: the mff intake allows reducing the severity of the hemorrhoidal disease symptoms during conservative treatment. in addition, the detralex® efficacy has been proven in postoperative pain reduction for patients diagnosed with varicose veins of the lower extremities. the investigators intend to evaluate the feasibility of the preoperative mff administration for the postoperative pain reduction and the decrease of the postoperative complications in patients with hemorrhoidal disease.


Eligibility criteria:
inclusion criteria: * stage 2-4 hemorrhoidal disease; * presence of indications for elective surgery (open hemorrhoidectomy) using mono or bipolar coagulation possibly combined with other minimally invasive methods: hemorrhoidopexy and mucopexy, ligasure hemorrhoidectomy; * absence of other diseases that cause pain; * class i, ii asa anesthesia risk; exclusion criteria: * the presence of the following diseases: paraproctitis, inflammatory bowel disease, metabolic or endocrine disorders, alcoholism, drug use, blood clotting disorders, and history of diseases in the anorectal region; * contraindicated or technically impossible subarachnoid anesthesia; * patients who refused to participate; * pregnant women.
serum metabolomics study of traditional chinese medicine formula （shen qi tiao ti formula） intervention to polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is a most common, heterogeneous, complex endocrinopathy disease.traditional chinese medicine (tcm) has been used in the treatment of pcos for many years. however, the mechanism underlying tcm remains obscure and challenging.in the present study, a metabolomics approach based on ultra-high-performance liquid chromatography (uplc) coupled with linear ion trap orbi-trap mass spectrometer (ltq orbi-trap ms) is used to investigate serum metabolic changes of tcm intervention to pcos.


Eligibility criteria:
inclusion criteria: * pcos diagnostic criteria: according to the diagnostic criteria revised by the european society of human reproduction and embryology and the american society for reproductive medicine at the rotterdam in 2003, pcos patients can be diagnosed if two of the three criteria are present after excluding congenial adrenal hyperplasia, cushing's syndrome, androgen secreting tumors, or other related disorders. the three criteria are (1) oligo- and/or anovulation; (2) clinical and/or biochemical signs of hyperandrogenism (clinical manifestations of hyperandrogenism include presence of acne, hirsutism, and androgenic alopecia); (3) polycystic ovaries by ultrasound examination: presence of 12 or more follicles in each ovary measuring 2-9 mm on diameter and/or ovarian volume\>10 ml. * age between 14 and 40 years. * 2 years after menarche exclusion criteria: * administration of other medications known to affect reproductive function or metabolism within the past three months, including oral contraceptives, gonadotropin-releasing hormone (gnrh) agonists and antagonists, anti androgens, gonadotropins, anti-obesity drugs, chinese herbal medicines, anti diabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, and calcium channel blockers. * patients with other endocrine disorders including 21-hydroxylase deficiency, hyperprolactinemia, uncorrected thyroid disease, suspected cushing's syndrome. * patients with known severe organ dysfunction or mental illness.
study to evaluate efficacy and safety of romosozumab compared with bisphosphonates in children and adolescents with osteogenesis imperfecta

Conditions: Osteogenesis Imperfecta

Summary: the primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (bmd) z-score at 6-months.


Eligibility criteria:
inclusion criteria: * participant has provided informed consent/assent prior to initiation of any study specific activities/procedures. or * participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent and the participant has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated. * ambulatory male and female children and adolescents, age 5 to \<18 years, including ambulatory with assistance as defined in the pediatric osteogenesis imperfecta (oi) population. * clinical diagnosis of oi, defined as clinical history consistent with type i, iii, or iv oi as determined by presence of expected phenotype (examples include: facial shape, voice, blue sclera, dentinogenesis imperfecta, typical radiographic features, fracture pattern) and lack of additional features unrelated to type i, iii, or iv oi (eg, blindness, mental retardation, neuropathy, and craniosynostosis). o if familial, also must be autosomal dominant. * meets at least one of the following: * 3 or more fractures within the previous 2 years, or * 1 or more nonvertebral fracture(s) within the previous 2 years and at least 1 prevalent vertebral fracture, or * 2 or more prevalent vertebral fractures. exclusion criteria: disease related * history of an electrophoresis pattern inconsistent with type i, iii or iv oi. * history of known mutation in a gene other than collagen type i alpha 1/collagen type i alpha 2 (col1a1/col1a2) causing oi or other metabolic bone disease. * history of congenital dislocation of the radial head, interosseous membrane calcification, or exuberant callus formation.

Keywords: osteogenesis imperfecta romosozumab evenity® bisphosphonates
multi-omics model predicts efficacy of preoperative neoadjuvant chemoradiotherapy combined pd-1 antibody therapy for locally advanced rectal cancer

Conditions: Colorectal Neoplasms

Summary: the purpose of this clinical research is to establish a multi-omics model based on genomics，transcriptomics，gut microbiota in predicting pathologic response after neoadjuvant chemoradiotherapy combined pd-1 antibody given to patients with locally advanced rectal cancer.


Eligibility criteria:
inclusion criteria: * patients have been fully aware of the content of this study and signed the informed consent voluntarily; * patients with rectal cancers must satisfied all the following conditions: stage ii/iii larc (ct1-3n1-2m0)；tumor distal location ≤ 7 cm from anal verge (mri diagnosed); * patients regardless of gender with aged ≥18 years and ecog score of 0 or 1; * physical and viscera function of patients can withstand major abdominal surgery; * patients are willing and able to follow the study protocol during the study; * patients give consent to the use of blood and pathological specimens for study; * within 28 days prior to enrolment, we must confirm a negative serological pregnancy test for child-bearing age women and they agree to use effective contraception for the duration of drug use and for 60 days after the last dose. exclusion criteria: * patients have a present or previous active malignancy except the diagnosis of rectal cancer this time; * patients underwent major surgery within 4 weeks prior to study treatment; * patients have any condition affects the absorption of capecitabine through gastrointestinal tract; * patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases; * patients who are allergic to any of the ingredients under study; * patients with severe concomitant diseases with estimated survival ≤ 5 years; * patients with present or previous moderate or severe liver and kidney damage presently or previously; * patients have received other study medications or any immunotherapy currently or in the past; * patients preparing for or previously received organ or bone marrow transplant; * patients who received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to the initiation of study therapy; * patients with congenital or acquired immune deficiency (such as hiv infection); * if patients with a history of uncontrolled epilepsy, central nervous system disease or mental disorder, the investigator will determine whether the clinical severity prevents the signing of informed consent or affects the patient's oral medication compliance; * patients with other factors that may affect the study results or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring combined treatment and severe laboratory examination abnormalities. * pregnant or lactating women
facilitating positive adaptation to breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to test the effects of a 10-wk cognitive behavioral stress management (cbsm) intervention vs. a single-day psycho-educational seminar on psychosocial adaptation and physiological adaptation in women being treated for stage i-iii breast cancer.

the study tests the effects of a 10-wk group-based cognitive behavioral stress management (cbsm) intervention (relaxation, stress awareness, cognitive restructuring, coping skills training, interpersonal skills training) versus a single-day psycho-educational seminar (general information about stress and coping) in women who have recently had surgery for breast cancer but have not yet started adjuvant therapy. the study evaluates the effects of cbsm on psychosocial adaptation (includes measures of negative adaptation \[distress and social disruption\] and positive adaptation \[benefit finding and positive affect\]) at 6-month and 12-month follow-up. the study also evaluates the effects of cbsm on physiological adaptation (includes levels of pm serum cortisol and t-helper-type 1 (th1) cytokine \[interleukin-2, il-2, and interferon-gamma, ifn-g, production after anti-cd3 stimulation of peripheral blood mononuclear cells (pbmc).

Eligibility criteria:
inclusion criteria: -women diagnosed with breast cancer at stage iii or below who had recently undergone lumpectomy or mastectomy exclusion criteria: * prior cancer, * prior psychiatric treatment for a serious disorder (e.g., psychosis, suicidality), * lack of fluency in english and had begun adjuvant therapy at time of first assessment

Keywords: stress management intervention breast cancer quality of life psychosocial adaptation
resuscitation table height for face-mask ventilation in infants

Conditions: Asphyxia; Resuscitation; Newborn Morbidity

Summary: positive pressure ventilation (ppv) is the most important intervention in neonatal resuscitation. during ppv, it is important to hold the face-mask with care, as applying excessive pressure could cause injury to the infant, while insufficient pressure could be a contributor of mask leak and reduced effective ventilation. application of positive pressure to face structures may trigger a vagally mediated reflex via the trigeminal nerve that innervates the skin of the face leading to apnoea and a decrease in heart rate (tcr, trigeminal-cardiac reflex). the force exerted by providers during neonatal ventilation to improve mask seal might result in pressure lesions and the elicitation of the trigeminal-cardiac reflex. the height of the resuscitation could influence the forces applied to the face and the quality of the procedure. information about the applied forces in relation to the height of the resuscitation table is unknown.


Eligibility criteria:
inclusion criteria: * level iii neonatal intensive neonatal care unit consultants and pediatric residents exclusion criteria: * none
efficacy and safety evaluation of azimilide or sotalol vs placebo for treatment of patients with atrial fibrillation.

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (a type of abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. the primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation. the double-blind, placebo-controlled phase of this study is designed to evaluate the efficacy and safety of oral azimilide compared with placebo and with sotalol, an antiarrhythmic drug, in maintaining sinus rhythm in patients who require cardioversion (electric shock to correct heart rhythm) to correct atrial fibrillation. once this phase of the study is completed, a second phase with a different study design will be conducted. the second phase is an open-label, follow-up phase to the first study. the follow-up phase will continue to evaluate the long-term safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.


Eligibility criteria:
inclusion criteria: * documented (12-lead ecg) history of symptomatic atrial fibrillation occurring between 48 hours and 6 months before screening * require the procedure of cardioversion (electric shock to correct abnormal rhythm) * in the investigator's opinion, is likely to maintain sinus rhythm after cardioversion. * be anticoagulated according to the recommendations of the study group on atrial fibrillation of the european society of cardiology guidelines. exclusion criteria: * previously unsuccessful electrical cardioversions * failed to respond to any class iii antiarrhythmic drugs * qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
implementing spiritual care in inpatient palliative care

Conditions: Cancer; Heart Failure; Chronic Obstructive Pulmonary Disease; Lateral Sclerosis

Summary: the goal of this observational study is to is to ascertain the spiritual needs of palliative patients in a standardized manner using the spiritual needs questionnaire and to promptly address those needs by (specialized) spiritual care. to determine whether the effort of implementing the spiritual needs questionnaire on a sustainable basis on the one hand brings the expected benefit to the patients and on the other hand can be provided by the pastoral care personnel, at muenster university hospital (specialized) spiritual care interventions will be documented in detail and retrospectively and prospectively collected data will be compared.


Eligibility criteria:
inclusion criteria: * all individual indication for general and specialised palliative care in clinical setting/routine (e.g.): * progressive, malign tumours * progressive, chronic obstructive pulmonary disease * patients with progressive disease and limited life expectancy (\< ca. 12 months) * patients attended by palliative caregivers in counselling services or on palliative ward * life expectancy \> 2 weeks * sufficient comprehension of german language and writing that allows an autonomous or supported completion of the questionnaire. * existence of an independently signed written consent. exclusion criteria: * severe cognitive impairment * capacity for consent lacking or impaired * impaired comprehension of german language and writing that would not allow an autonomous or supported completion of the questionnaire.
correlation between smart phone overuse, craniovertebral angle, cervical muscle endurance and temporomandibular proprioception in adolescents

Conditions: Smart Phone Addiction; Craniovertebral Angle; Temporomandibular Proprioception; Adolescents

Summary: the study was done to: 1. investigate the correlation between smart phone overuse and craniovertebral angle in adolescents. 2. investigate the correlation between smart phone overuse and cervical muscle endurance in adolescents. 3. investigate the correlation between smart phone overuse and temporomandibular joint proprioception in adolescents.

this study was aimed to clarify the correlation between prolonged use of spinal traction on cervical curvature, muscle endurance, and temporomandibular joint proprioception in adolescents. it assisted physiotherapists in detecting and treating problems caused by prolonged spinal traction use, providing necessary precautions and treatments to prevent or alleviate this issue.

Eligibility criteria:
inclusion criteria: 1. both genders will be included. 2. adolescents with age ranging from 17 to 19 years. 3. adolescents using smart phone daily for not less than 4 years for 4 years. 4. all participants will be free from any medical disease, visual or hearing problem. 5. no history of temporomandibular joint complaints or disorder. exclusion criteria: 1. adolescent who cannot understand or follow instructions. 2. congenital or acquired spinal deformities. 3. adolescents with obesity. 4. athlete adolescents. 5. any neck or upper extremity injury. 6. neurological, musculoskeletal, and cardiopulmonary disease. 7. adolescent with teeth braces during last 4 years
antibiotic therapy in treating patients with low grade gastric lymphoma

Conditions: Lymphoma

Summary: rationale: antibiotics may stop the growth of helicobacter pylori which may be associated with gastric lymphoma. purpose: phase ii trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated.

objectives: i. determine the rate of eradication of helicobacter pylori using omeprazole, colloidal bismuth subcitrate, tetracycline, and metronidazole in patients with low grade gastric lymphoma. ii. determine the macroscopic/endoscopic and microscopic healing/remission rate after eradication of helicobacter pylori in this patient population. iii. determine the natural history of low grade gastric lymphoma after eradication of helicobacter pylori. outline: this is a nonrandomized, open label, multicenter study. patients receive oral omeprazole bid on days 1-10, oral bismuth subcitrate and oral tetracycline qid on days 4-10, and oral metronidazole tid on days 4-10. patients are evaluated at 8 weeks. patients who experience complete remission and are h. pylori negative proceed to follow up. patients with complete remission or no change but who are h. pylori positive proceed to a second course of therapy with the previous schedule or with omeprazole bid, amoxicillin qid, and clarithromycin tid for 14 days. patients who experience no change but are h. pylori negative are followed at 6 and 9 months and restaged. patients are followed at 6, 9, 12, 18, and 24 months, then annually thereafter. projected accrual: approximately 60-96 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven, previously untreated, low grade gastric lymphoma clinical stage i and ii1 no bulky disease no high grade component (grade 5 and 4, if monoclonality proven, allowed) documented presence/absence of h. pylori infection measurable and/or evaluable disease patient characteristics: age: 18 and over performance status: who 0-2 life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: not pregnant or lactating fertile patients must use effective contraception no prior or concurrent malignancies unless: at least 1 year remission low risk or recurrence no prior gastric malignancy no nonmalignant disease causing poor medical risk no allergy to omeprazole prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: no prior radiotherapy to the abdomen surgery: no prior gastric surgery except simple closure of perforated ulcer with or without wedge excision of the ulcer other: no prior therapy for gastric lymphoma at least 30 days since experimental therapy no other concurrent experimental therapy at least 30 days since antibiotics with activity against h. pylori

Keywords: contiguous stage ii marginal zone lymphoma contiguous stage ii small lymphocytic lymphoma stage i marginal zone lymphoma stage i small lymphocytic lymphoma extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue
frequency and type of genetic abnormalities found in antenatal corpus callosum malformation

Conditions: Corpus Callosum Malformation; Prenatal Disorder

Summary: corpus callosum malformation (ccm) is the most frequently detected cerebral defect diagnosed in the prenatal setting. the most common ccm is corpus callosum agenesis (cca) which is found in 2 to 3% of patients presenting with intellectual disability. when ccm is diagnosed, the risk of chromosomal disorder is estimated to be 16%, be it aneuploidy such as trisomy 18, trisomy 13 or mosaic trisomy 8, or a chromosome structure anomaly, copy number variation or more complex rearrangement in france, since 2013 oligoarray-based comparative genomic hybridization (acgh) analysis is performed in the prenatal period for most malformations after approval by a multidisciplinary prenatal diagnosis ethics committee (centre pluridisciplinaire de diagnostic prénatal, cpdpn) . however, to date only a few studies have been published which report recurrent copy number variations (cnv) associated with ccm and estimate the risk for a chromosomal disorder, thus making counseling difficult in this context of prenatal diagnosis.


Eligibility criteria:
inclusion criteria: * prenatal diagnosis of corpus callosum malformation, isolated or not, between 01/01/2013, and 31/05/2018 * fetal dna available * mother's informed consent obtained exclusion criteria: * no amniocentesis performed * refusing to participate
incidence of tinnitus amongst teenagers and young adults mp3 users

Conditions: Tinnitus

Summary: the aim of this study is to compare the incidence of tinnitus between mp3 users and non-users, aged between 15 and 30 years old. 100 patients will be recruited in valença secondary schools. high frequency audiometry and otoacoustic emissions will be performed.tinnitus patients will complete the tinnitus handicap inventory questionnaire.


Eligibility criteria:
inclusion criteria: * 15 to 30 years old * a-n tympanogram exclusion criteria: * muscular tinnitus * vascular tinnitus * somatosensorial tinnitus * concomitant tmj disorders * external and middle ear diseases * professional or recreative exposure to other noise sources other than mp3 players

Keywords: tinnitus mp3 players noise induced hearing loss high frequencies audiometry acoustic otoemissions